Masimo (MASI) Acquires PHASEIN AB in $30.4M Deal
Tweet Send to a FriendGet Alerts MASI Hot Sheet
Price: $21.84 --0%
Overall Analyst Rating:
NEUTRAL (
Up)
Dividend Yield: 4.6%
Revenue Growth %: +14.0%
Overall Analyst Rating:
NEUTRAL (
Up)Dividend Yield: 4.6%
Revenue Growth %: +14.0%
Trade MASI Now!
Masimo (NASDAQ: MASI), announced it has acquired PHASEIN AB (Stockholm, Sweden), a developer and manufacturer of ultra-compact mainstream and sidestream capnography, multigas analyzers, and handheld capnometry solutions.
The acquisition of PHASEIN's multigas technologies complements Masimo's breakthrough innovations for patient monitoring with a portfolio of products ranging from OEM solutions for external "plug-in-and-measure" gas analyzers and integrated modules to handheld devices. With multiple measurements delivered through either mainstream or sidestream options, Masimo customers can now benefit from CO2, N2O, O2, and anesthetic agent monitoring in many hospital environments, such as operating rooms, procedural sedations and intensive care units.
Masimo paid approximately $30.4 million in cash to purchase PHASEIN. No other terms were disclosed. The estimated impact of the acquisition on Masimo's 2012 financial results will be included in the company's second quarter earnings announcement, set for release after the market close today.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The acquisition of PHASEIN's multigas technologies complements Masimo's breakthrough innovations for patient monitoring with a portfolio of products ranging from OEM solutions for external "plug-in-and-measure" gas analyzers and integrated modules to handheld devices. With multiple measurements delivered through either mainstream or sidestream options, Masimo customers can now benefit from CO2, N2O, O2, and anesthetic agent monitoring in many hospital environments, such as operating rooms, procedural sedations and intensive care units.
Masimo paid approximately $30.4 million in cash to purchase PHASEIN. No other terms were disclosed. The estimated impact of the acquisition on Masimo's 2012 financial results will be included in the company's second quarter earnings announcement, set for release after the market close today.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Abercrombie & Fitch Co. (ANF) Misses Q1 EPS by 4c; Guides FY Below Views
- Saks (SKS) Surges on Report of Possible Sale
- Best Buy (BBY) Posts Q1 adj.-EPS of 32c; Comps Down 1.1%
Create E-mail Alert Related Categories
Mergers and AcquisitionsRelated Entities
Earnings
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
